Interaction of activated factor VII and active site-inhibited activated factor VII with tissue factor

Blood Coagulation and Fibrinolysis

Volumn 9, Issue SUPPL. 1, 1998, Pages

  Sorensen B B ^a   Rao, L V M ^b  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

Active site inhibited factor VIIa; Factor VIIa; Haemostasis; Thrombosis; Tissue factor

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; ENZYME PRECURSOR; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; THROMBOPLASTIN;

BINDING SITE; BLOOD CLOTTING; CELL DAMAGE; CELL SURFACE; CONFERENCE PAPER; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; THROMBOCYTE ACTIVATION; THROMBOGENESIS; THROMBOSIS;

BINDING SITES; DISEASE MODELS, ANIMAL; FACTOR VIIA; FIBRINOLYTIC AGENTS; HUMANS; PROTEIN BINDING; THROMBOPLASTIN;

EID: 0031727981     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Rapaport SI, Rao LVM. The tissue factor pathway: how it has become a prima-ballerina. Thromb Haemost 1995; 74:7-17.
2. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Am J Pathol 1989; 134:1087-1097.
3. Fleck RA, Rao LVM, Rapaport SI, Varki N. Localization of human tissue factor antigen by immunostaining with monospecific polyclonal anti-human tissue factor antibody. Thromb Res 1990; 59:421-437.
4. Camerer E, Kolsto AB, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996; 81:1-41.
5. Østerud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost 1983; 49:5-7.
6. Rao LVM. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev 1992; 11:246-266.
7. Taubman MB, Fallon JT, Schecter AD, Giesen P, Mendlowitz M, Fyfe BS, et al. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost 1997; 78:200-204.
8. Warr TA, Rao LV, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75:1481-1489.
9. Taylor FB Jr, Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett R. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33:127-134.
10. Taylor FB Jr, Chang A, Mather T, Catlett R, Blick K, Esmon CT. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by E. coli without preventing shock or organ damage. Blood 1991; 78:364-368.
11. Biemond BJ, Levi M, ten Cate H, Soule HR, Morris LD, Foster DL, et al. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal fab fragment against factor VII/VIIa. Thromb Haemost 1995; 73:223-230.
12. Creasey AA, Chang ACK, Feigen L, Wün TC, Taylor FB, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91:2850-2860.
13. Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997; 78:471-477.
14. Ragni M, Golino P, Cirillo P, Pascucci I, Scognamiglio A, Ravera A, et al. Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis. Cardiologia 1996; 41:51-58.
15. Jang YS, Guzman LA, Lincoff AM, Gottsaunerwolf M, Forudi F, Hart CE, et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral-artery injury model. Circulation 1995; 92:3041-3050.
16. Harker LA, Hanson SR, Wilcox JN, Kelly AB. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis 1996; 26:76-82.
17. Wildgoose P, Bregengard C, Nordfang O. Infusion of inactivated factor VIIa inhibits endotoxin induced disseminated intravascular coagulation in rabbits [abstract]. Thromb Haemost 1993; 69:780.
18. Arnljots B, Ezban M, Hedner U. Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa. J Vasc Surg 1997; 25:341-346.
19. Ruf W, Mueller BM. Requirement for factor VII binding and catalytic function in TF-dependent hematogenous tumor cell metastasis [abstract]. Thromb Haemost 1997; (suppl):594.
20. Ørvim U, Barstad RM, Orning L, Petersen LB, Ezban M, Hedner U, Sakariassen KS. Inactivated active-site recombinant fVIIa is an efficient inhibitor of tissue factor-fVIIa induced arterial thrombus formation in human blood [abstract]. Thromb Haemost 1995; 73:1185.
21. Kirchhofer D, Tschopp TB, Baumgartner HR. Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex-vivo thrombosis model. Arterioscler Thromb Vasc Biol 1995; 15:1098-1106.
22. Zivelin A, Rao LVM, Rapaport SI. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin-K-dependent clotting factors. J Clin Invest 1993; 92:2131-2140.
23. Zivelin A, Rao LVM, Rapaport SI. Evidence for an essential role of tissue factor-dependent blood-coagulation in the pathogenesis of the local Shwartzman reaction. Blood Cells Mol Dis 1995; 21:9-19.
24. Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 1986; 25:4007-4020.
25. Higashi S, Matsumoto N, Iwanaga S. Molecular mechanism of tissue factor-mediated acceleration of factor VIIa activity. J Biol Chem 1996; 271:26569-26574.
26. Dickinson CD, Ruf W. Active site modification of factor VIIa affects interactions of the protease domain with tissue factor. J Biol Chem 1997; 272:19875-19879.
27. Kjalke M, Oliver JA, Monroe DM, Hoffman M, Ezban M, Hedner U, Roberts HR. The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. Thromb Haemost 1997; 78:1202-1208.
28. Sørensen BB, Persson E, Freskgard P-O, Kjalke M, Ezban M, Williams T, Rao LVM. Incorporation of an active-site inhibitor in factor VIIa alters the affinity for tissue factor. J Biol Chem 1997; 272:11863-11868.
29. Sakai T, Lund-Hansen T, Paborsky L, Pedersen AH, Kisiel W. Binding of human factors VII and VIIa to a human bladder carcinoma cell line (J82). J Biol Chem 1989; 264:9980-9988.
30. Le DT, Rapaport SI, Rao LVM. Relations between factor VIIa binding and expression of factor VIIa/tissue factor catalytic activity on cell surfaces. J Biol Chem 1992; 267:15447-15454.
31. Le DT, Rapaport SI, Rao LVM. Studies of the mechanism for enhanced cell surface factor VIIa/tissue factor activation of factor X on fibroblast monolayers after their exposure to N-ethylmaleimide. Thromb Haemost 1994; 72:848-855.
32. Banner DW, D'Arcy A, Chène C, Winkler FK, Guha A, Konigsberg WH, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380:41-46.